Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 110 111 112 113 114 ... 140 »» | Laatste | Omlaag ↓
  1. [verwijderd] 31 juli 2007 18:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Previous Close 1.00 Bid/Tick 1.03
    Open 1.03 Bid Size 6,100
    Day's High 1.04 Ask 1.04
    Day's Low 1.01 Ask Size 9,400
    Volume 67,523 52 Week Range 0.96-1.58


    weinig omzet...als dat een beetje gaat lopen is het ....prrrrrrrrrrt up
  2. [verwijderd] 31 juli 2007 18:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Previous Close 1.00 Bid/Tick 1.03
    Open 1.03 Bid Size 17,300
    Day's High 1.04 Ask 1.04
    Day's Low 1.01 Ask Size 9,200
    Volume 68,023 52 Week Range 0.96-1.65

  8. [verwijderd] 31 juli 2007 20:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Previous Close 1.00 Bid/Tick 1.04
    Open 1.03 Bid Size 400
    Day's High 1.07 Ask 1.05
    Day's Low 1.01 Ask Size 2,900
    Volume 116,506 52 Week Range 0.96-1.65

  19. maxl1 2 augustus 2007 14:49

    • maxl1

      Lid sinds: 29 aug 2001

      Laatste bezoek: 18 feb 2025

    • Aanbevelingen

      Ontvangen: 1

      Gegeven: 0

    •    Aantal posts: 77

    GTC BIOTHERAPEUTICS AND LFB BIOTECHNOLOGIES DEVELOPING CD20 ANTIBODY
    FRAMINGHAM, MA and PARIS, FRANCE – August 2, 2007 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LFBBiotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.), announced today that they have initiated development of a transgenically produced CD20 monoclonal antibody under the existing agreement between GTC and LFB Biotechnologies. The resulting product is expected to have target specificity similar to Rituximab (Rituxan®, Mabthera®) and to have relatively higher antibody dependent cell-mediated cytotoxicity, or ADCC. The existing relevant CD20 antibody patents will expire by 2014. The transgenically produced CD20 antibody is anticipated to be commercially developed for oncology and auto-immune indications. Rituximab is used in the treatment of B-cell non-Hodgkin’s lymphoma, B-cell leukemia and rheumatoid arthritis. It is also under investigation for a range of auto-immune conditions such as systemic lupus erythematosus, immune thrombocytopenic purpura (ITP), and type-1 diabetes. Rituximab had worldwide sales of nearly $4 billion in 2006 and is projected to have a $5 billion market by 2010.



    “Rituximab, an antibody targeting CD20, has proven its therapeutic value in Non Hodgkin’s Lymphoma and rheumatoid arthritis,” stated Yann Echelard, Ph.D., Vice President of Research and Development for GTC. “We believe our transgenic production technology enables us to develop an anti-CD20 monoclonal antibody which may have clinical benefits due to enhanced ADCC and provide an attractive price to the market to encourage broader use.”



    “Transgenic production has the capability to drive economically beneficial large-scale production of the CD20 antibody,” stated Sami Chtourou, Ph.D., Director Biopharmaceutical Development and Transgenesis Program for LFB. “The enhanced ADCC characteristics have the potential to establish a product that may offer efficacy benefits or reduced dosing requirements for patients.”



    This CD20 antibody may be considered for clinical development as a follow-on biologic in the US and a biosimilar in the EU as the appropriate legislation is enacted and regulatory guidance is established.



    The transgenically produced CD20 antibody is being developed under the agreement between GTC and LFB established in October 2006. Costs and profits from the program are anticipated to be shared 50/50. GTC will have exclusive marketing rights in the US and Canada. LFB will have exclusive marketing rights in the EU. GTC and LFB have co-exclusive marketing rights to the rest of the world. LFB has initially demonstrated production of this CD20 antibody with enhanced ADCC in cell culture.



    Production in the milk of transgenic goats is anticipated to be established in 2008 with an investigational new drug application to the US Food and Drug Administration planned for 2010.



    Non-Hodgkin Lymphoma, or NHL, is a group of cancers originating in the lymphatic system that is characterized by the malignant transformation of lymphocytes. NHL has an incidence rate of about 20 cases per 100,000 population in the United States, and a worldwide incidence of 5 –15 per 100,000. It is more prevalent in males and occurs at an average age of 50. The incidence of NHL in the US rose 84% from 1975 to 2004, an average yearly increase of 2.8%. NHL is the fifth most common cancer in the United States, where an estimated 63,000 new cases of NHL will be diagnosed in 2007, and where the National Cancer Institute estimates that 18,660 deaths due to NHL will occur (approximately 5% of all US cancer deaths).



    CD20 is an antigen located on the surface of mature B-lymphocytes and B-cell derived tumor cells. The CD20 monoclonal antibody recruits the body's natural defenses to target marked B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment.



    About LFB Group

    With sales of 268 million euros, LFB is the fourth largest pharmaceutical company supplying drugs to hospitals in France and a major European producer of plasma-derived medicinal products. LFB provides to healthcare professionals a wide range of 19 plasma-derived medicinal products in three therapeutic fields: Hemostasis, Anesthesia-intensive Care and Immunology. LFB's medicinal products are prescribed to address emergencies but also to manage chronic diseases that require lifelong treatment. With 1300 employees, among which 200 are in R&D, LFB is recognized as one of the major European players in the field of therapeutic proteins with expertise in protein downstream processing, characterization as well as biological safety and viral clearance. LFB focuses its discovery and development activities on monoclonal antibodies and therapeutic proteins for rare and severe diseases. Ideally placed to become a driving force in new technological and therapeutic fields, LFB can use its technology platform to develop highly cytotoxic antibodies while its R&D portfolio contains high-potential projects calling on innovative technology.



    About GTC Biotherapeutics

    GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval anywhere in the world for a transgenically produced protein whenATryn®, a recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. GTC’s intellectual property includes a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal as well as a patent application for enhanced ADCC. GTC’s t
2.783 Posts
Pagina: «« 1 ... 110 111 112 113 114 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.016
AB InBev 2 5.495
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.610
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.612
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.747
Aedifica 3 909
Aegon 3.258 322.708
AFC Ajax 538 7.088
Affimed NV 2 6.296
ageas 5.844 109.891
Agfa-Gevaert 14 2.049
Ahold 3.538 74.331
Air France - KLM 1.025 35.034
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.770
Allfunds Group 4 1.470
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.836 243.003
AMG 971 133.250
AMS 3 73
Amsterdam Commodities 305 6.689
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.994
Apollo Alternative Assets 1 17
Apple 5 381
Arcadis 252 8.772
Arcelor Mittal 2.033 320.686
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.300
Aroundtown SA 1 219
Arrowhead Research 5 9.731
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.093
ASML 1.766 106.796
ASR Nederland 21 4.469
ATAI Life Sciences 1 7
Atenor Group 1 485
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.661
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392

Macro & Bedrijfsagenda

  1. 19 februari

    1. Handelsbalans januari (Jap)
    2. Ontex Q4-cijfers
    3. ASR Q4-cijfers
    4. Philips Q4-cijfers
    5. Vopak Q4-cijfers
    6. Consumenten- en producentenprijzen januari (VK)
    7. HSBC Q4-cijfers (VK)
    8. Hypotheekaanvragen wekelijks (VS)
    9. Woningbouw en bouwvergunningen januari (VS)
    10. Aedifica Q4-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda